New drug trial aims to halt debilitating 'Second Skeleton' disease
NCT ID NCT06508021
Summary
This study is testing an experimental drug called andecaliximab for people with fibrodysplasia ossificans progressiva (FOP), a rare and severe condition where muscles and soft tissues turn into bone. The main goal is to see if the drug can safely reduce the formation of new, abnormal bone growths and lessen painful flare-ups. The trial involves about 92 children and adults and compares the drug against a placebo for up to a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBRODYSPLASIA OSSIFICANS PROGRESSIVA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
University of California San Francisco (UCSF)
San Francisco, California, 94143, United States
-
University of Pennsylvania - Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.